In summary, this meta-analysis has revealed that durable antitumor clinical benefit can be achieved with anti-PD-1/PD-L1 monotherapy in a subset of patients with advanced breast cancer patients, and suggested that this treatment was generally well tolerated and had a manageable safety profile with most AEs at low grade. This evidence concerns the gene CD274 and breast cancer.